German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.
Florian Pröll, managing director at Tübingen-based Biametrics, said in a statement that the company "looks forward to expanding our collaboration in the field of biomolecular interaction analysis" with MorphoSys.
Biametrics and MorphoSys have been working together in the area of high-throughput antibody screening. According to Biametrics, in a pilot study, they used Biametrics' label-free B-screen microarray platform to characterize Fab fragment antigen interactions.
Biametrics recently launched B-screen as a research tool, and a handheld instrument called B-portable that relies on the same label-free technology is set for introduction later this year.
Markus Enzelberger, senior vice president and head of discovery alliances and technologies at MorphoSys, said in a statement that MorphoSys views B-screen as a "promising technology in the field of epitope mapping."
MorphoSys is based in Martinsried, Germany. The company maintains a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease.